20240016941. COMBINATION THERAPY simplified abstract (Antabio SAS)

From WikiPatents
Jump to navigation Jump to search

COMBINATION THERAPY

Organization Name

Antabio SAS

Inventor(s)

Martin Everett of Labege (FR)

Simon Leiris of Labege (FR)

David Thomas Davies of Labege (FR)

Nicolas Sprynski of Labege (FR)

Lilha Beyria of Labege (FR)

Thomas David Pallin of Margate (GB)

Andrew Peter Cridland of Margate (GB)

Toby Jonathan Blench of Margate (GB)

Richard Leonard Elliott of Margate (GB)

David Edward Clark of Margate (GB)

COMBINATION THERAPY - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240016941 titled 'COMBINATION THERAPY

Simplified Explanation

The invention described in the patent application is a combination of a compound called an indane and one or more CFTR modulators. The compound can be in the form of formula (i) or a pharmaceutically acceptable salt. The patent also includes pharmaceutical compositions containing these combinations.

  • The invention involves a compound called an indane and CFTR modulators.
  • The compound can be represented by formula (i) or a pharmaceutically acceptable salt.
  • The patent includes pharmaceutical compositions containing these combinations.
  • The invention has therapeutic uses in the treatment of conditions such as cystic fibrosis.

Potential Applications:

  • Treatment of cystic fibrosis and other related conditions.

Problems Solved:

  • Lack of effective treatment options for cystic fibrosis.
  • Limited efficacy of current CFTR modulators.

Benefits:

  • Improved treatment options for cystic fibrosis patients.
  • Enhanced efficacy of CFTR modulators.


Original Abstract Submitted

the invention provides a combinations and pharmaceutical compositions comprising (i) a compound which is an indane according to formula (i) or a pharmaceutically acceptable salt thereof; and (ii) one or more cftr modulator; wherein r, r, r, r, n, lk, (a), g and m are as defined herein. also provided are therapeutic uses of such combinations and compositions in the treatment of conditions such as cystic fibrosis.